CDKN2A and neoplasm: Both his relapsed cf-tDNA sample and recurrent tumor tissue were detected to have newly emerging CDKN2A:p.L16Pfs*9 and PDGFRA:p.V536E mutations compared to the initial tissue (Figure 2B), indicating that the relapsed tumor had evolved more malignant branches featured with CDKN2A loss (20).